Business
-
GW Pharmaceuticals has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance in response to its patent application for a metered dose spray device for sublingual delivery of… Read more . . .
-
Galapagos subsidiary Argenta has signed an agreement with Boehringer Ingelheim to provide respiratory drug discovery services for “an undisclosed target within Boehringer Ingelheim’s respiratory disease portfolio,” the company said. On its website, Argenta says that… Read more . . .
-
Besins Healthcare will license the Muco (μco) intranasal system from Shin Nippon Biomedical Laboratories (SNBL) for delivery of its BHR-310 progesterone powder, which it is developing for the treatment of mild traumatic brain injury (TBI).… Read more . . .
-
According to Celsus Therapeutics, it has received patents for several of its pipeline drugs, including MRX-4, and intranasal multifunctional anti-inflammatory drug for the treatment of allergic rhinitis. Celsus changed its name from Morria Biopharmaceuticals in… Read more . . .
-
Allergan, which recently acquired MAP Pharmaceuticals, has announced that it has received a Complete Response Letter (CRL) from the FDA in regard to its NDA for Levadex inhaled dihydroergotamine for the treatment of migraines. The… Read more . . .
-
According to Asthmapolis, the company has raised $5 million in Series A financing from The Social+Capital Partnership (“Social Capital”) that it will use to “deliver new innovations and services for its comprehensive solution of sensors,… Read more . . .
-
Device design and manufacturing company Nypro plans to build a device manufacturing facility in Waterford, Ireland and, according to the company, will hire 200 workers to staff the new plant. Nypro’s capabilities include injection molding… Read more . . .
-
Actavis says that it will launch 0.25 mg and 0.5 mg vials of its generic budesonide inhalation suspension immediately after the United States District Court for the District of New Jersey ruled that the products… Read more . . .
-
Inhalation experts from the Woolcock Institute of Medical Research and the University of Sydney have launched a new company called Pulmatix to provide analytical services ranging from evaluation of APIs and formulations in respiratory cells… Read more . . .
-
Savara Pharmaceuticals has received additional funding for Phase 2 development of its AeroVanc vancomycin inhalation powder for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients. The company brought its Series B… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden